Regeneron Pharmaceuticals

Regeneron Pharmaceuticals has an exceptionally strong balance sheet with a conservative debt-to-equity ratio of 0.06x. The company could comfortably weather a severe economic downturn. This financial fortress provides strategic flexibility and reduces risk for long-term shareholders.